Search results for " insulin"

showing 10 items of 237 documents

Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and de…

2015

Abstract Objectives Severe hypoglycemia is associated with cognitive decline and dementia in older persons with type 2 diabetes. The role of antidiabetic treatments on severe hypoglycemia is unknown in dementia. The aims were to determine the prevalence of severe hypoglycemic events and investigate associations among severe hypoglycemic and specific antidiabetic treatments (classes of oral agents and types of insulin analogs) in a large sample of nursing home patients with diabetes according to dementia status. Design Cross-sectional observational study. Setting A total of 150 nursing homes across Italy. Participants A total of 2258 patients with type 2 diabetes (dementia = 1138, no dementi…

Blood GlucoseMaleAgingSevere hypoglycemia dementia insulin analogs antidiabetic oral agents agingmedicine.medical_treatmentInsulin analogAdministration OralType 2 diabetesSeverity of Illness IndexInsulin AntagonistsReference ValuesOdds RatioPrevalenceHomes for the AgedInsulinReference ValueCognitive declineNursing (all)2901 Nursing (miscellaneous)General NursingAged 80 and overInsulin AntagonistMedicine (all)Health PolicyAging; Antidiabetic oral agents; Dementia; Insulin analogs; Severe hypoglycemia; Administration Oral; Age Distribution; Aged; Aged 80 and over; Blood Glucose; Confidence Intervals; Cross-Sectional Studies; Dementia; Diabetes Mellitus Type 2; Female; Homes for the Aged; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Antagonists; Italy; Logistic Models; Male; Middle Aged; Nursing Homes; Odds Ratio; Prevalence; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sex Distribution; Sulfonylurea Compounds; Nursing (all)2901 Nursing (miscellaneous); Health PolicyGeneral MedicineMiddle AgedPrognosisSulfonylurea CompoundNursing HomeItalyFemaleHumanmedicine.medical_specialtyLogistic ModelPrognosiHypoglycemiaelderly patientsRisk AssessmentAge DistributionInternal medicineDiabetes mellitusmedicineConfidence IntervalsDementiaHumansHypoglycemic AgentsSex DistributionAgedAntidiabetic oral agentCross-Sectional StudieSevere hypoglycemiaHypoglycemic Agentbusiness.industryInsulinOdds ratiomedicine.diseaseHypoglycemiaNursing HomesEndocrinologyCross-Sectional StudiesLogistic ModelsSulfonylurea CompoundsDiabetes Mellitus Type 2DementiaGeriatrics and GerontologybusinessConfidence IntervalBody mass indexJournal of the American Medical Directors Association
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

Real-time estimation of plasma insulin concentration from continuous glucose monitor measurements

2015

Continuous glucose monitors can measure interstitial glucose concentration in real time for closed-loop glucose control systems, known as artificial pancreas. These control systems use an insulin feedback to maintain plasma glucose concentration within a narrow and safe range, and thus to avoid health complications. As it is not possible to measure plasma insulin concentration in real time, insulin models have been used in literature to estimate them. Nevertheless, the significant interand intra-patient variability of insulin absorption jeopardizes the accuracy of these estimations. In order to reduce these limitations, our objective is to perform a real-time estimation of plasma insulin co…

Blood GlucoseMaleInsulin pump0209 industrial biotechnologymedicine.medical_treatmentBiomedical EngineeringArtificial pancreas030209 endocrinology & metabolismBioengineering02 engineering and technologyArtificial pancreas03 medical and health sciencesExtended Kalman filter020901 industrial engineering & automation0302 clinical medicineComputer SystemsTime estimationmedicineHumansInsulinComputer SimulationObservabilityMathematicsType 1 diabetesBlood Glucose Self-MonitoringInsulinReproducibility of ResultsGlucose insulin modelsGeneral MedicineMiddle AgedModels Theoreticalmedicine.diseaseINGENIERIA DE SISTEMAS Y AUTOMATICAExtended Kalman filterComputer Science ApplicationsHuman-Computer InteractionDiabetes Mellitus Type 1Type 1 diabetesFemalePlasma insulinMATEMATICA APLICADAAlgorithmsInsulin estimationBiomedical engineeringComputer Methods in Biomechanics and Biomedical Engineering
researchProduct

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism

2018

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes. Methods: The study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) follow…

Blood GlucoseMaleProteomicstype 2 diabetes mellitusmedicine.medical_treatmentType 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexImpaired glucose tolerance0302 clinical medicineInsulinInsulin-Like Growth Factor INutrition and DieteticsbiologyChemistryComplement C4aFabaceaeMiddle AgedHealthy Volunteerslcsh:Nutrition. Foods and food supplyNutritive SweetenersAdultmedicine.medical_specialtyAdolescentsweetenerBlood sugarlcsh:TX341-641030209 endocrinology & metabolismCarbohydrate metabolismArticleDiabetes Mellitus ExperimentalBeveragesinsulin-like growth factor03 medical and health sciencesYoung AdultInsulin resistanceDouble-Blind MethodInternal medicineDiabetes mellitusGlucose IntolerancemedicineAnimalsHumansC4A complementAgedGlycated HemoglobinPlant ExtractsInsulinOverweightmedicine.diseaseRatsRats Zuckerimpaired glucose tolerance; type 2 diabetes mellitus; sweetener; insulin-like growth factor; C4A complementDisease Models AnimalEndocrinologyimpaired glucose toleranceDiabetes Mellitus Type 2biology.proteinGLUT2InositolFood ScienceNutrients; Volume 10; Issue 3; Pages: 271
researchProduct

“The Linosa Study”: Epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate

2009

Abstract Background and aims Growing evidence suggests that the metabolic syndrome (MetS) has both a genetic and environmental basis. To evaluate the possibility of a further genetic analysis, we estimated prevalence rates and heritabilities for the MetS and its individual traits in the adult population of Linosa, a small and isolated Italian Island in the southern-central part of the Mediterranean Sea. Methods and results The Linosa Study (LiS) group consisted of 293 Caucasian native subjects from 51 families (123 parents; 170 offsprings). The MetS was defined according to NCEP/ATP III criteria and the following prevalence rates were calculated: hyperglycaemia 20.3%; central obesity 34.9%;…

Blood GlucoseMaleSettore MED/09 - Medicina InternaGenetic LinkageEndocrinology Diabetes and MetabolismPrevalenceMedicine (miscellaneous)Settore MED/13 - EndocrinologiaGenetic Linkage; Young Adult; Age Factors; Metabolic Syndrome X; Cholesterol HDL; Hypertriglyceridemia; Sex Factors; Humans; Aged; Italy; Blood Glucose; Smoking; European Continental Ancestry Group; Adult; Middle Aged; Insulin Resistance; Adolescent; Male; FemaleSettore MED/49 - Scienze Tecniche Dietetiche ApplicateMetabolic SyndromeHypertriglyceridemiaeducation.field_of_studySettore M-EDF/01 - Metodi e Didattiche delle Attivita' MotorieNutrition and DieteticsMetabolic Syndrome XSmokingAge FactorsMiddle AgedCholesterolItalyAdolescent; Adult; Age Factors; Aged; Blood Glucose; Cholesterol HDL; European Continental Ancestry Group; Female; Genetic Linkage; Humans; Hypertriglyceridemia; Insulin Resistance; Italy; Male; Metabolic Syndrome X; Middle Aged; Sex Factors; Smoking; Young AdultFemaleCardiology and Cardiovascular MedicineGenetic isolateAdultmedicine.medical_specialtyWaistHDLAdolescentEuropean Continental Ancestry GroupPopulationBiologyWhite PeopleYoung AdultSex FactorsInsulin resistanceInternal medicinemedicineHumanseducationAgedCholesterol HDLnutritional and metabolic diseasesmetabolic syndromeHeritabilityInsulin resistanceMetabolic syndromeObesityHeritabilitymedicine.diseaseObesityEndocrinologySettore MED/03 - Genetica MedicaInsulin ResistanceMetabolic syndromeDemographyNutrition, Metabolism and Cardiovascular Diseases
researchProduct

GLP-2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet

2015

Glucagon like peptide-2 (GLP-2) is a gastrointestinal hormone released in response to dietary nutrients, which acts through a specific receptor, the GLP-2 receptor (GLP-2R). The physiological effects of GLP-2 are multiple, involving also the intestinal adaptation to high fat diet (HFD). In consideration of the well-known relationship between chronic HFD and impaired glucose metabolism, in the present study we examined if the blocking of the GLP-2 signaling by chronic treatment with the GLP-2R antagonist, GLP-2 (3-33), leads to functional consequences in the regulation of glucose metabolism in HFD-fed mice. Compared with animals fed standard diet (STD), mice at the 10th week of HFD showed hy…

Blood GlucoseMaleTime FactorsDiet High-FatPeptide FragmentsMice Inbred C57BLDisease Models AnimalHormone Antagonistsobesity insulin resistance pancreatic isletsInsulin-Secreting CellsGlucagon-Like Peptide 2AnimalsHomeostasisInsulinGLP-2; obesity insulin resistance pancreatic isletsGLP-2BiomarkersGlucose Metabolism DisordersSignal Transduction
researchProduct

Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth h…

2014

Purpose: To evaluate the performance of various indexes of insulin sensitivity and secretion and to identify the most useful indicator of deterioration of glucose metabolism in a cohort of children with growth hormone (GH) deficiency (GHD) during GH treatment. Methods: In 73 GHD children (55 M, 18 F; mean age 10.5 years) at baseline and after 12 months of treatment, we evaluated a number of surrogate indexes of insulin secretion and sensitivity. In a subgroup of 11 children we also performed an euglycemic hyperinsulinemic clamp. Results: After 12 months, a significant increase in fasting glucose (p < 0.001) and HbA1c levels (p < 0.001) was documented, despite all children remained with a no…

Blood GlucoseMalemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentChildren; Glucose metabolism; Growth hormone treatment; Insulin secretion; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyHypopituitarismCarbohydrate metabolismHypopituitarismSettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceInsulin-Secreting CellsInternal medicinemedicineHormone replacement therapy (male-to-female)HumansInsulinGrowth hormone treatmentChildDwarfism PituitaryChildrenGlucose metabolismGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryInsulin secretionInsulinGlucose Tolerance TestInsulin sensitivitymedicine.diseaseGrowth hormone treatmentTreatment OutcomeEndocrinologyChild PreschoolConcomitantFemaleInsulin Resistancebusiness
researchProduct

Long-term parameters of heart rate variability in patients with insulin-resistance.

2019

Heart rate variability (HRV) is defined as the oscillation in both the interval between consecutive heartbeats (considered RR intervals) and consecutives measures of instantaneous heart rates.1 HRV measures the cardiac autonomic function noninvasively1,2 and its reduction is an independent risk factor for cardiovascular events.3 Insulin-resistance is a pathological condition, in which the body’s cells become resistant to insulin effects.4 The aim of our study was to evaluate the relationship between insulin-resistance and the reduction of HRV parameters.

Blood GlucoseMalemedicine.medical_specialtyTime FactorsMEDLINEPilot ProjectsHeart rate variability insulin-resistanceInsulin resistanceHeart RateInternal medicineHeart ratemedicineHeart rate variabilityHumansInsulinIn patientAgedRetrospective StudiesMetabolic SyndromeInsulin bloodbusiness.industryRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseTerm (time)CardiologyFemaleInsulin ResistanceCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis.

2015

Aims/Introduction According to some authors, in type 2 diabetes there is a reduced postprandial action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, little is known about the role of fasting incretins in glucose homeostasis. Our aim was to evaluate, through a two-step cluster analysis, the possibility of phenotyping patients with type 2 diabetes at onset on the basis of fasting GLP-1, GIP and ghrelin. Materials and Methods A total of 96 patients with type 2 diabetes within 6 months of onset (mean age 62.40 ± 6.36 years) were cross-sectionally studied. Clinical, anthropometric and metabolic parameters were evaluated. At fasting the follow…

Blood GlucoseMalemedicine.medical_treatmentEndocrinology Diabetes and MetabolismSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineGlucagon-Like Peptide 1Glucose homeostasisCluster AnalysisHomeostasis030212 general & internal medicineGeneral MedicineArticlesMiddle AgedGlucagon-like peptide-1GhrelinGlucagon‐like peptide‐1PhenotypeClinical Science and CareFemaleOriginal Articlehormones hormone substitutes and hormone antagonistsGlucagon-like peptide-1medicine.medical_specialtyGlucose-dependent insulinotropic polypeptideIncretin030209 endocrinology & metabolismGastric Inhibitory PolypeptideGhrelin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Endocrinology Diabetes and Metabolism; Internal MedicineIncretins03 medical and health sciencesInsulin resistanceGlucose‐dependent insulinotropic polypeptideInternal medicineDiabetes mellitusmedicineInternal MedicineHumansAgedAdiponectinbusiness.industryInsulinmedicine.diseaseEndocrinologyGlucosechemistryDiabetes Mellitus Type 2Glycated hemoglobinInsulin ResistancebusinessJournal of diabetes investigation
researchProduct